Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 12/20 | 0.71 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.50 |
| ▸ | OXTR | P30559 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3082472 | 0.83 | AVPR1A (1.00) | AVPR1AHSD11B1CHRM1 | |
| SCHEMBL3093900 | 0.77 | AVPR1A (0.65) | AVPR1AOXTRCHRM1 | |
| SCHEMBL825280 | 0.77 | AVPR1A (0.67) | AVPR1AOXTR | |
| SCHEMBL825279 | 0.76 | HSD11B1 (0.47) | AVPR1AHSD11B1CHRM1ADRA1DADRA1A | |
| SCHEMBL614997 | 0.76 | AVPR1A (1.00) | AVPR1AOXTR | |
| SCHEMBL615021 | 0.75 | AVPR1A (0.71) | AVPR1AOXTR | |
| SCHEMBL825236 | 0.75 | AVPR1A (0.62) | AVPR1AHSD11B1OXTR | |
| SCHEMBL28771078 | 0.74 | AVPR1A (0.63) | AVPR1AOXTRCHRM1 | |
| SCHEMBL614897 | 0.73 | AVPR1A (0.75) | AVPR1AOXTR | |
| SCHEMBL615518 | 0.73 | AVPR1A (0.85) | AVPR1AHSD11B1OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143281-B2 | Indoles | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | claimed |
| EP-2125785-B1 | INDOLE-3-YL-CARBONYL-PIPERIDINE- DERIVATIVES FOR THE TREATMENT OF ANXIETY AND DEPRESSIVE DISORDERS VIA V1A RECEPTOR ANTAGONISM | HOFFMANN LA ROCHE (CH) | 2011-11-16 | — | — | EP | claimed |
| WO-2011132443-A1 | SURFACE ACOUSTIC WAVE DEVICE AND MANUFACTURING METHOD OF SAME | 株式会社村田製作所 (JP) | 2011-10-27 | — | — | WO | claimed |
| EP-2125785-A1 | INDOLES | F. Hoffmann-Roche AG (CH) | 2009-12-02 | — | — | EP | claimed |
| WO-2008080842-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | WO | claimed |
| US-20080161316-A1 | INDOLES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | claimed |
| US-8143281-B2 | Indoles | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143281-B2 | Indoles | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143281-B2 | Indoles | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2125785-B1 | INDOLE-3-YL-CARBONYL-PIPERIDINE- DERIVATIVES FOR THE TREATMENT OF ANXIETY AND DEPRESSIVE DISORDERS VIA V1A RECEPTOR ANTAGONISM | HOFFMANN LA ROCHE (CH) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011132443-A1 | SURFACE ACOUSTIC WAVE DEVICE AND MANUFACTURING METHOD OF SAME | 株式会社村田製作所 (JP) | 2011-10-27 | — | — | WO | disclosed |
| EP-2125785-A1 | INDOLES | F. Hoffmann-Roche AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008080842-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | WO | disclosed |
| US-20080167344-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | US | disclosed |
| US-20080161315-A1 | INDOLES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161315-A1 | INDOLES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161315-A1 | INDOLES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161316-A1 | INDOLES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161316-A1 | INDOLES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161316-A1 | INDOLES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161315-A1 | INDOLES | AVPR1A, HTR1A, AVPR1B | AVPR1A 1/4885HSD11B1 916/4885OXTR 28/4885 |
| US-20080167344-A1 | INDOLES | AVPR1A, HTR1A, AVPR1B | AVPR1A 1/4885HSD11B1 916/4885OXTR 28/4885 |
| US-20080161316-A1 | INDOLES | AVPR1A, HTR1A, AVPR1B | AVPR1A 1/4885HSD11B1 916/4885OXTR 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.